WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Miranda Biven
Partner
Technology Transactions
San Diego
Palo Alto
mbiven@wsgr.com

D858-350-2338

Download vCard
Open PDF
  • Life Sciences Experience

    Miranda represents growing and established life sciences companies in partnering and licensing arrangements, M&A deals, and other transactions.

  • Comprehensive Transactional Experience

    Miranda's experience includes IP-based matters, including R&D, manufacturing, supply, and distribution agreements.

  • Complex Biotech Agreement Experience

    Miranda has helped clients forge clinical trials arrangements; materials transfer agreements; and commercialization and co-commercialization agreements.

Miranda Biven is a partner in the technology transactions practice and a previous member of the board of directors at Wilson Sonsini Goodrich & Rosati. Her practice focuses on the life sciences industry, representing public and private companies based in the United States and abroad in complex partnering and licensing arrangements, mergers, acquisitions, divestitures, spin-outs, and other business arrangements. Miranda counsels clients on the legal and business issues associated with such transactions, as well as the full spectrum of technology and intellectual property-based agreements, including research and development agreements; manufacturing, supply, and distribution agreements; clinical trials arrangements; materials transfer agreements; and commercialization and co-commercialization agreements. She also regularly represents clients in their dealings with academic institutions and other not-for-profit organizations.

Prior to joining Wilson Sonsini in 2005, Miranda practiced in New York and Sydney, Australia.

Experience

Miranda Biven is a partner in the technology transactions practice and a previous member of the board of directors at Wilson Sonsini Goodrich & Rosati. Her practice focuses on the life sciences industry, representing public and private companies based in the United States and abroad in complex partnering and licensing arrangements, mergers, acquisitions, divestitures, spin-outs, and other business arrangements. Miranda counsels clients on the legal and business issues associated with such transactions, as well as the full spectrum of technology and intellectual property-based agreements, including research and development agreements; manufacturing, supply, and distribution agreements; clinical trials arrangements; materials transfer agreements; and commercialization and co-commercialization agreements. She also regularly represents clients in their dealings with academic institutions and other not-for-profit organizations.

Prior to joining Wilson Sonsini in 2005, Miranda practiced in New York and Sydney, Australia.

Education
  • LL.M., Harvard Law School
  • B.A. (First Class Honours), University of Sydney
  • LL.B. (First Class Honours), University of Sydney
Honors
  • Honored among San Diego Business Journal’s 2025 “Women of Influence in Law”
  • Named among 2025 "Leaders of Influence in Technology" by San Diego Business Journal
  • Recognized among 2023 "Leaders of Influence in Life Sciences" by San Diego Business Journal
  • Recognized as a 2023 “Top Health Care Lawyer” by the Daily Journal
Admissions
  • State Bar of California
  • State Bar of New York
Credentials
Education
  • LL.M., Harvard Law School
  • B.A. (First Class Honours), University of Sydney
  • LL.B. (First Class Honours), University of Sydney
Honors
  • Honored among San Diego Business Journal’s 2025 “Women of Influence in Law”
  • Named among 2025 "Leaders of Influence in Technology" by San Diego Business Journal
  • Recognized among 2023 "Leaders of Influence in Life Sciences" by San Diego Business Journal
  • Recognized as a 2023 “Top Health Care Lawyer” by the Daily Journal
Admissions
  • State Bar of California
  • State Bar of New York
Focus Areas
  • Biotech
  • Global Generics
  • Life Sciences
  • Medical Devices
  • Technology Transactions
Recent Insights
Client Highlights
Wilson Sonsini Advises Saturnus Bio on Strategic Collaboration with Merck KGaA, Darmstadt, Germany
On June 23, 2026, Merck KGaA, Darmstadt, Germany, a leading global science and technology company, announced a strategic collaboration with Versant Ventures to launch Saturnus Bio, a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet need. Wilson Sonsini Goodrich & Rosati advised Saturnus Bio on the transaction.

The research-stage partnership entails a build-to-buy deal structure, including an upfront payment of $50 million from Merck KGaA, Darmstadt, Germany to fund Saturnus Bio’s research activities, securing a minority equity stake in the company, as well as additional success-based preclinical milestones, supporting the development of novel drug candidates for genetic cardiomyopathy patients. Merck KGaA, Darmstadt, Germany has exclusive rights to acquire Saturnus Bio for a pre-determined option payment, in addition to success-based earnouts.

The Wilson Sonsini team that advised Saturnus Bio on the transaction includes:
Learn More
Client Highlights
Firm Advises Denali Therapeutics on Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
On June 18, 2026, Denali Therapeutics, a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle™ platform, announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million. Wilson Sonsini Goodrich & Rosati advised Denali on the transaction.
Learn More
View All
Recent Events
WSGR Events
Biotech's New Playbook: Spinouts and Optionality
Biotechnology companies are increasingly using single-asset spinouts as a way to create value, though the approach can be complex. This afternoon forum will examine considerations to strategically design and execute a successful spinout. Attendees will gain insight into the legal foundations of these transactions, including tax considerations, patent strategy, IP allocation, and structural design. The program will also explore the broader business drivers behind spinout decisions—such as capital formation, strategic focus, partnership alignment, governance, and long-term value creation.
Learn More
Affiliated Programs
Biocom San Diego CEO Summit 2025
Wilson Sonsini is proud to support the Biocom San Diego CEO Summit, the premier conference designed exclusively for life science CEOs in the San Diego region.
Learn More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.